8-O-Acetylharpagide
8-O-Acetylharpagide has anti-inflammatory, vasoconstrictor, antibacteria and antiviral activities, it also has a biological activity on isolated smooth muscle preparations from guinea pig. 8-O-Acetylharpagide presents the obvious inhibition on Epstein-Barr virus(EBV) infection, it not only apparently inhibits EBV-VCA,but also alleviates the hyperfunction and effusion of capillary permeability at the early inflammation.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
J Cell Biochem.2018, 119(2):2231-2239
J Cosmet Dermatol.2022, 21(1):396-402.
J Holistic Integrative Pharm.2023, 4(1):14-28
J Nat Prod.2022, doi: 10.1021
Food Chem.2023, 427:136647.
Microchemical Journal2023, 194:109249
Food Sci Nutr.2023, 00:1-10.
J Sep Sci.2020, 43(22):4148-4161.
Acta Physiologiae Plantarum2016, 38:7
Sci Rep. 2018, 10590
Related and Featured Products
J Nat Prod. 1992 Aug;55(8):1145-8.
Vasoconstrictor activity of 8-O-acetylharpagide from Ajuga reptans.[Pubmed:
1431938]
The traditional therapeutic indications for the use of Ajuga reptans (Labiatae) have been investigated. The H2O-soluble part of a crude and partially purified MeOH extract and two isolated iridoids (8-O-Acetylharpagide and harpagide), were tested for a biological activity on isolated smooth muscle preparations from guinea pig.
Insect Biochem Mol Biol. 2001 Oct;31(11):1077-82.
8-O-acetylharpagide is not an ecdysteroid agonist.[Pubmed:
11520686]
METHODS AND RESULTS:
We have reinvestigated the activity of 8-O-Acetylharpagide, an iridoid glucoside, as an ecdysteroid agonist. Elbrecht et al. (Insect Biochem. Mol. Biol. 26 (1996) 519) isolated a preparation of this compound from Ajuga reptans L. and ascribed ecdysteroid agonist activity on the basis of the induction of an ecdysteroid-like response in Drosophila melanogaster KcO cells, the displacement of [3H]ponasterone A from the Drosophila receptor and the activation of an ecdysteroid-regulated gene in a transactivation assay. We provide evidence that the agonist activity derives from contaminating ecdysteroids; A. reptans is a species rich in ecdysteroids.
CONCLUSIONS:
Purified 8-O-Acetylharpagide is not active in the D. melanogaster B(II) cell bioassay, neither as an agonist nor as an antagonist, nor does it displace [3H]ponasterone A from dipteran or lepidopteran ecdysteroid receptor complexes.
Zhongguo Zhong Yao Za Zhi. 2013 Jun;38(12):2015-8.
Pharmacokinetics of 8-O-acetylharpagide and harpagide after oral administration of Ajuga decumbens extract in beagle dog.[Pubmed:
24066603]
8-O-Acetylharpagide and harpagide are two kinds of effective component of Ajuga decumbens extract. A sensitive LC-MS/MS method has been established for pharmacokinetics of 8-O-Acetylharpagide and harpagide in beagle dog after oral administration of from A. decumbens extract.
METHODS AND RESULTS:
Female beagle dogs received orally 12.9, 25.7 mg x kg(-1) p. o. Concentrations of 8-O-Acetylharpagide and harpagide in plasma were determined by LC-MS/MS method at different time points and all pharmacokinetic parameters were estimated by non-compartment analysis. The mobile phase consisted of 0.1% formic acid in water (A) and acetonitrile (B), which was run at a flow rate of 0.3 mL x min(-1). Chromatographic separation was achieved on an Agilent ZORBAX XDB-C18 column (2.1 mm x 50 mm, 3.5 microm) using a gradient elution of 5% B at 0-2 min, 95% B at 2. 1-5 min and 5% B at 5. 1-10 min. All analytes, including the IS, were monitored under positive ionization conditions and quantified in MRM mode with transitions of m/z 429.2-369.2 for 8-O-Acetylharpagide, m/z 387.2-207.2 for harpagide, and m/z 149.2-103.1 for IS. High purity nitrogen was employed as both the nebulizing and drying gas. Other parameters of the mass spectrometer were optimized as follows: drying gas flow 10.0 L x min(-1); drying gas temperature 300 degrees C; capillary voltage 4 000 V. Results showed that 8-O-Acetylharpagide and harpagide showed a dose-dependence profile. T(max) of 8-O-Acetylharpagide is 1.7 h, and T(max) of harpagide is 1.57 h, which was higher than T(max) of 8-O-Acetylharpagide and harpagide after oral administration of from A. decumbens extract in rats.
CONCLUSIONS:
The different pharmacokinetic parameters may be due to the species differences of rat and beagle dog.
World Journal of Integrated Traditional & Western Medicine, 2013, 8(4):351-4.
In Vivo and In Vitro Pharmacodynamics Study of 8-O-Acetylharpagide in the Prevention and Treatment of EB Viral Infection.[Reference:
WebLink]
To assess the pharmacodynamic effects of 8-O-Acetylharpagide in the prevention and treatment of Epstein-Barr virus(EBV)by in vivo and in vitro trial.
METHODS AND RESULTS:
The real-time fluorescent quantitative PCR(Real-time RT-PCR)technology was used to observe the inhibition of 8-O-Acetylharpagide on EBV viral capsid antigen(VCA)in B95-8 cell.By the intraperitoneal injection of acetic acid,the model of the increased celiac capillary permeability was prepared in mice for the detection of the inhibition of 8-O-Acetylharpagide on the hyperfunction and effusion of capillary permeability at the early inflammation. In the high-dose,middle-dose and low-dose groups,8-O-Acetylharpagide presented obvious inhibition on EBV-VCA in B95-8 separately(P0.01).In the high-dose and middle-dose groups,8-O-Acetylharpagide inhibited significantly the increased celiac capillary permeability in the mice induced by acetic acid(P0.01).
CONCLUSIONS:
8-O-Acetylharpagide presents the obvious inhibition on EBV infection.It not only apparently inhibits EBV-VCA,but also alleviates the hyperfunction and effusion of capillary permeability at the early inflammation.
